Sarcopenic obesity

There are 1,140 papers on sarcopenic obesity in aging research: 60 trials and 646 observational studies in people, 39 in animals, 1 in cells, 379 reviews. The newest story, Nov 7, 2026: “Intervals added more muscle in older adults with sarcopenic obesity”.

Disease

1,140 papers study it265 more mention it952 findings

51 new papers in 30 daysSee all 1,405 papers on sarcopenic obesity

At a glance

Human observational studies link sarcopenic obesity with frailty and cognitive impairment, and with higher mortality in dialysis patients. A human trial reports reduced sarcopenic obesity with semaglutide; a power-training trial reports improvement in older women with sarcopenic obesity. A study following major abdominal cancer surgery finds no clear link with postoperative complications.

952 findings in 550 papers from 2004 to 2026, 82 of them since April 2026

“At discharge, 80 patients (42.55%) were no longer classified as sarcopenic and showed significant improvements in HGS.”
Muscle Strength and Phase Angle Are Potential Markers for the Efficacy of Multidisciplinary Weight-Loss Program in Patients with Sarcopenic ObesityJournal of clinical medicine2024doi:10.3390/jcm13175237
  • Human trial60
  • Humans646
  • Animals39
  • Cells1
  • In silico4

Interventions

23

Semaglutide

downin humans1

1 study
  1. Semaglutide decreases sarcopenic obesity in humans (49% at baseline to 33% at M12).

    “the prevalence of sarcopenic obesity decreased from 49% at baseline to 33% at M12”

    Human trial2.4 mgbaseline to 12 monthsn = 106

    Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study

    Diabetes, obesity & metabolism

  2. Semaglutide decreases sarcopenic obesity in humans (49% to 33%).

    “Patients with sarcopenic obesity decreased significantly from baseline (49%) to M12 (33%).”

    Human trial12 monthsn = 106

    Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study

    Diabetes, obesity & metabolism

More on Semaglutide

Power training

downin humans1−36% reversal

1 study
  1. Power training decreases sarcopenic obesity in older women with sarcopenic obesity (35.7% reversal).

    “Notably, 35.7% of the participants in the PT group (n = 5) achieved normalization of the key parameters—muscle mass, strength, and BMI—indicating full reversal of the SO condition.”

    Human trialin older women with sarcopenic obesity32 weeksn = 5

    Efficacy of Power Training on Sarcopenic Obesity in Community-Dwelling Older Women: A 32-Week Randomized Clinical Trial

    Nutrients

  2. Power training decreases sarcopenic obesity in humans (sarcopenic obesity) (35.7%).

    “Notably, 35.7% of the PT participants no longer met diagnostic criteria for SO after the intervention.”

    Human trialsarcopenic obesity32-weekfemalesn = 40

    Efficacy of Power Training on Sarcopenic Obesity in Community-Dwelling Older Women: A 32-Week Randomized Clinical Trial

    Nutrients

More on Power training

Incretin therapy

downin humans1

1 study
  1. Incretin therapy decreases sarcopenic obesity in humans.

    “Conversely, incretin therapy can reduce the prevalence of sarcopenic obesity and mitigate myosteatosis”

    Review

    Comparative incidence of sarcopenia across distinct GLP-1 receptor agonists in non-diabetic populations

    International Health Sciences Review

More on Incretin therapy

Parity

no changein humans1

1 study
  1. Parity was not clearly linked with sarcopenic obesity in humans after multivariable adjustment.

    “Higher parity and hypertension showed significant associations in univariate analysis, but lost significance after adjustment.”

    Humansafter multivariable adjustmentfemalesn = 86

    Prevalence and Determinants of Sarcopenic Obesity in Reproductive and Postmenopausal Women: A Cross-Sectional Study

    Bangladesh Journal of Endocrinology and Metabolism

More on Parity

Androgen deprivation therapy

upin humans1

1 study
  1. Androgen deprivation therapy induces sarcopenic obesity in humans (prostate cancer).

    “Although ADT contributes substantially to disease control, it also induces significant adverse metabolic and body composition changes. These alterations include loss of lean mass, increased fat mass, and deterioration in muscle quality”

    Reviewprostate cancer

    Myosteatosis and Sarcopenic Obesity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Rationale for Mechanism-Driven Multimodal Intervention

    Cancers

More on Androgen deprivation therapy

Mifepristone

upin mice1

1 study
  1. Mifepristone induces sarcopenic obesity in mice (bilateral orchiectomy).

    “chronic mifepristone administration induced obese sarcopenia, hepatic steatosis and insulin resistance, accelerated thymus aging, but prevented bone loss in male mice.”

    Animalsbilateral orchiectomy30 mg/kg every other day28 daysmales

    Chronic mifepristone administration induces obese sarcopenia, hepatic steatosis and insulin resistance in androgen-deprived male mice

    The Journal of steroid biochemistry and molecular biology

More on Mifepristone

GLP-1-based therapy discontinuation

upin reviews1

1 study
  1. GLP-1-based therapy discontinuation increases sarcopenic obesity.

    “sarcopenic obesity, driven by preferential fat mass recovery relative to lean mass”

    Review

    Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap

    Cureus

More on GLP-1-based therapy discontinuation

Early-onset type 2 diabetes

upin humans1

1 study
  1. Early-onset type 2 diabetes is linked with higher sarcopenic obesity in humans (compared with late-onset type 2 diabetes).

    “Patients with EOT2D exhibited a higher prevalence of sarcopenic obesity compared to those with LOT2D.”

    Humanscompared with late-onset type 2 diabetes

    Sarcopenic obesity increases the risk of falls in early-onset type 2 diabetes

    Journal of endocrinological investigation

More on Early-onset type 2 diabetes

Combined microbiota modulation, dietary optimization and exercise

downin reviews1

1 study
  1. Combined microbiota modulation, dietary optimization and exercise decreases sarcopenic obesity.

    “personalized strategies combining microbiota modulation, dietary optimization, and exercise can be used to counteract SO”

    Review

    Multifactorial Mechanisms and Therapeutic Role of the Gut Microbiota in Sarcopenic Obesity: Role of Lifestyle and Gut Microbiota-Derived Metabolites

    Nutrition reviews

More on Combined microbiota modulation, dietary optimization and exercise

Light physical activity

no changein humans1

1 study
  1. Light physical activity was not clearly linked with sarcopenic obesity in humans (participants meeting the MVPA recommendation).

    “LPA was not associated with SO risk among participants meeting the MVPA recommendation”

    Humansparticipants meeting the MVPA recommendationn = 862

    Accelerometer-Determined Physical Activity and Sarcopenic Obesity Risk in Older European Men and Women

    Journal of cachexia, sarcopenia and muscle

More on Light physical activity

Bariatric surgery

downin humans1

1 study
  1. Bariatric surgery decreases sarcopenic obesity in humans (89.3% to 2.9%).

    “Before BS, SO prevalence in the overall sample was 89.3%, decreasing to 2.9% after BS.”

    Human trial1 yearfemalesn = 140

    Effects of Bariatric Surgery on Sarcopenic Obesity Outcomes: A One-Year Prospective Study in Middle-Aged Women

    Obesity surgery

More on Bariatric surgery

Cholecalciferol

no changein humans1

1 study
  1. Cholecalciferol showed no clear effect on sarcopenic obesity in humans (overweight older adults) (3.7% in LDG vs. 0.9% HDG, p = 0.18).

    “no significant differences were noted in the proportion of patients with SO at study entry (1.8% in LDG vs 1.6% HDG; p = 0.99) and at 12 months (3.7% in LDG vs. 0.9% HDG; p = 0.18) across arms.”

    Human trialoverweight older adults3750 IU/day vs 600 IU/day12 monthsn = 248

    Effect of high dose vitamin D supplementation on indices of sarcopenia and obesity assessed by DXA among older adults: A randomized controlled trial

    Endocrine

More on Cholecalciferol

All 23

Effects

61

Physical function

downin humans14no changein humans2OR 3.31

16 studies
  1. Sarcopenic obesity is linked with worse physical function in patients with MASLD.

    “SO individuals showed greater hepatic steatosis, more metabolic comorbidities and demonstrated poorer physical performance.”

    Humansin patients with MASLDn = 200

    Evaluation of Sarcopenic Obesity in Patients with MASLD

    Medical sciences (Basel, Switzerland)

  2. Sarcopenic obesity is linked with worse physical function in humans (p = 0.022 to p < 0.001).

    “Regardless of definition, participants with sarcopenic obesity were older; had lower walking speed, grip strength, and balance; and exhibited higher prevalence of conventional sarcopenia, knee osteoarthritis, and reduced mobility function”

    Humansn = 736

    Clinical characteristics and survival in sarcopenic obesity defined by the Japanese working group on sarcopenic obesity criteria versus existing definitions in older adults: findings from the Otassha study

    International journal of obesity (2005)

  3. Sarcopenic obesity is linked with worse physical function in humans (COPD) (p <0.001).

    “Patients with COPD+SO had more pronounced impairments of their physical activity according to the 6MW and 5.squat-stand tests ( p <0.001).”

    HumansCOPDmales

    The Impact of Sarcopenic Obesity on the Course of Chronic Obstructive Pulmonary Disease in Elderly Men

    Tuberculosis and lung diseases

  4. Sarcopenic obesity is linked with worse physical function in humans (early breast cancer) (7.5 ± 0.2 s vs 6.6 ± 0.2 s and 6.8 ± 0.1 s).

    “TUG was worse in SO (7.5 ± 0.2 s) than both Eutrophic (6.6 ± 0.2 s) and Obesity (6.8 ± 0.1 s-p < 0.01).”

    Humansearly breast cancerfemalesn = 66

    The ESPEN and EASO Criteria for Sarcopenic Obesity in Early Breast Cancer: Association With Physical Function, Fatigue and Quality of Life

    Psycho-oncology

  5. Sarcopenic obesity is linked with worse physical function in humans (advanced knee osteoarthritis and BMI ≥35 kg/m2) (7.2, p = 0.046).

    “worse WOMAC function score, 7.2 (p = 0.046)”

    Humansadvanced knee osteoarthritis and BMI ≥35 kg/m2n = 50

    Sarcopenic obesity prevalence and clinical implications in patients with advanced knee osteoarthritis and class II-III obesity

    Clinical nutrition ESPEN

  6. Sarcopenic obesity is linked with worse physical function in humans.

    “The SO group exhibited the poorest functional performance.”

    Humans

    Pinch strength and its variability: Novel insights into functional decline in sarcopenic obesity

    Nutrition (Burbank, Los Angeles County, Calif.)

  7. Sarcopenic obesity is linked with worse physical function in humans (community-dwelling older adults) (ß: -16.53).

    “SO was significantly associated with frailty (OR 4.71), impaired function (ß: -16.53), and mobility limitations (OR 5.73).”

    Humanscommunity-dwelling older adultsn = 202

    The Impact of Sarcopenic Obesity on Frailty, Cognition, and Function in Community-Dwelling Older Adults

    Journal of frailty, sarcopenia and falls

  8. Sarcopenic obesity is linked with worse physical function in humans (sarcopenic obesity) (95% CI 1.001-1.137).

    “Sarcopenic obesity was associated with muscle-specific strength (95% IC 0.016-0.241), and TUG (95% CI 1.001-1.137).”

    Humanssarcopenic obesityfemalesn = 156

    Analysis of body composition, functionality and muscle-specific strength of older women with obesity, sarcopenia and sarcopenic obesity: a cross-sectional study

    Scientific reports

  9. Sarcopenic obesity is linked with worse physical function in older patients with COPD (p = 0.041).

    “Moreover, sarcopenia and SO had lower results than obesity (p = 0.001, p = 0.041, respectively).”

    Humansin older patients with COPDn = 124

    Body compositions phenotypes of older adults with COPD

    Frontiers in nutrition

  10. Sarcopenic obesity was not clearly linked with physical function in humans (sufficiently active).

    “sufficiently active older adults did not present a significant reduction in muscle strength in the lower limbs and physical performance.”

    Humanssufficiently active

    Sarcopenic obesity does not impair lower limb strength and physical performance in sufficiently active older adults: a cross-sectional study

    Scientific reports

All 16

Quality of life

downin humans5

5 studies
  1. Sarcopenic obesity is linked with lower quality of life in humans (early breast cancer) (61.6 ± 7.2 vs 81.1 ± 6.9).

    “Global health/QoL (p = 0.03) was lower in SO (61.6 ± 7.2) and Obesity (60.4 ± 3.7) than Eutrophic (81.1 ± 6.9).”

    Humansearly breast cancerfemalesn = 66

    The ESPEN and EASO Criteria for Sarcopenic Obesity in Early Breast Cancer: Association With Physical Function, Fatigue and Quality of Life

    Psycho-oncology

  2. Sarcopenic obesity is linked with lower quality of life in humans (advanced knee osteoarthritis and BMI ≥35 kg/m2) (-14.7, p = 0.016).

    “lower EQ-5D visual analog score, -14.7 (p = 0.016), compared to those without SO.”

    Humansadvanced knee osteoarthritis and BMI ≥35 kg/m2n = 50

    Sarcopenic obesity prevalence and clinical implications in patients with advanced knee osteoarthritis and class II-III obesity

    Clinical nutrition ESPEN

  3. Sarcopenic obesity is linked with worse quality of life in patients with solid tumor cancers.

    “SO was also associated with poorer QoL”

    Humansin patients with solid tumor cancersn = 6,790

    Sarcopenic Obesity and Outcomes for Patients With Cancer

    JAMA network open

  4. Sarcopenic obesity impairs quality of life in humans.

    “the multifaceted detrimental effects on elderly quality of life and life expectancy”

    Review

    Diagnosis and prevention of sarcopenic obesity should be emphasized

    Zhonghua yi xue za zhi

  5. Sarcopenic obesity impairs quality of life in humans.

    “Sarcopenic obesity, or the loss of muscle mass and function associated with excess adiposity, is a largely untreatable medical condition associated with diminished quality of life”

    Review

    Sarcopenic obesity: emerging mechanisms and therapeutic potential

    Metabolism: clinical and experimental

Cognitive function

downin humans4HR 1.2

4 studies
  1. Sarcopenic obesity is linked with worse cognitive function in humans (β = -0.96, 95% CI -1.80 to -0.13).

    “Sarcopenic obesity was associated with poor global cognition (MoCA-T: β ̂ = -0.96; 95% confidence interval [CI] -1.80 to -0.13)”

    Humans2-year follow-upn = 366

    Consensus-Defined Sarcopenic Obesity and a Related Dynapenic Obesity Phenotype in Relation to Early Cognitive Impairment

    Journal of cachexia, sarcopenia and muscle

  2. Sarcopenic obesity is linked with worse cognitive function in humans (hospitalized frail or prefrail patients).

    “The SO group had the highest prevalence of cognitive impairment and life activity dependency.”

    Humanshospitalized frail or prefrail patientsn = 206

    Cognitive impairment mediates the association between sarcopenic obesity and daily living ability in the frail older population

    Experimental gerontology

  3. Sarcopenic obesity is linked with worse cognitive function in AD patients.

    “The sarcopenia and SO groups exhibited worse global cognitive function compared to the normal and obesity groups.”

    Humansin AD patients

    Relationship between sarcopenic obesity and cognitive function in patients with mild to moderate Alzheimer's disease

    Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society

  4. Sarcopenic obesity is linked with worse cognitive function in humans (HR 1.20, 95% CI 1.03-1.40).

    “sarcopenic obesity (HR 1.20; 95% CI 1.03-1.40)”

    Humans8 yearsn = 5,822

    Incident Impaired Cognitive Function in Sarcopenic Obesity: Data From the National Health and Aging Trends Survey

    Journal of the American Medical Directors Association

Handgrip strength

downin humans4

4 studies
  1. Sarcopenic obesity is linked with worse handgrip strength in humans (hospitalized older adults) (all p < 0.01).

    “Patients with SO had worse ADL, IADL, MNA-SF scores, and lower handgrip strength (all p < 0.01).”

    Humanshospitalized older adultsn = 364

    Sarcopenic obesity is linked to worse clinical outcomes than sarcopenia or obesity alone in hospitalized older adults

    BMC geriatrics

  2. Sarcopenic obesity is linked with lower handgrip strength in humans (sarcopenic obesity).

    “Compared to women without SO, those with the condition had lower handgrip strength”

    Humanssarcopenic obesityfemalesn = 145

    A proposal for a fat mass index criterion for the assessment of sarcopenic obesity in the community-dwelling older women

    Clinical nutrition ESPEN

  3. Sarcopenic obesity is linked with worse handgrip strength in humans (p < 0.05).

    “SO negatively explained the variability of handgrip strength (p < 0.05).”

    Humans

    Sarcopenic obesity does not impair lower limb strength and physical performance in sufficiently active older adults: a cross-sectional study

    Scientific reports

  4. Sarcopenic obesity is linked with lower handgrip strength in sufficiently active older adults (ꞵ = -0.210, p < 0.05).

    “Multiple linear regression showed that SO negatively explained the variability of handgrip strength (model 2: ꞵ=-0.210; p < 0.05), even when adjusted for confounding variables.”

    Humansin sufficiently active older adultsn = 72

    Defying Age: can active older adults with sarcopenic obesity overcome muscle strength and physical performance losses?

    Research SquarePreprint

Activities of daily living

downin humans3

3 studies
  1. Sarcopenic obesity is linked with lower activities of daily living in humans (sarcopenic obesity) (p = 0.002 (ADL)).

    “Patients in the SO group demonstrated significantly lower scores in functional and cognitive assessments, including ADL, IADL, MMSE, and MNA”

    Humanssarcopenic obesityn = 364

    Sarcopenic Obesity in Older Adults: A More Dependent, Frail, and Even Fatal Condition than Sarcopenia or Obesity Alone. A Retrospective Cross-Sectional Study

    Preprints.orgPreprint

  2. Sarcopenic obesity is linked with worse activities of daily living in humans (individuals with spinal cord injury) (54 vs. 69 points, p = 0.006).

    “Participants with sarcopenic obesity (54 vs. 69 points, p = 0.006) had significantly lower FIM motor scores than those without this condition.”

    Humansindividuals with spinal cord injuryn = 82

    Association Between Sarcopenic Obesity and Activities of Daily Living in Individuals with Spinal Cord Injury

    Journal of clinical medicine

  3. Sarcopenic obesity is linked with worse activities of daily living in humans (post-acute rehabilitation after stroke) (β = −0.048, p = 0.031).

    “In multivariate analyses, sarcopenic obesity was independently and negatively associated with FIM-motor (β = −0.048, p = 0.031) and FILS at discharge (β = −0.095, p = 0.046) in women.”

    Humanspost-acute rehabilitation after strokefemalesn = 352

    The Applicability of the ESPEN and EASO-Defined Diagnostic Criteria for Sarcopenic Obesity in Japanese Patients after Stroke: Prevalence and Association with Outcomes

    Nutrients

Higher-level functional capacity

no changein humans2downin humans1

2 studies
  1. Sarcopenic obesity was not clearly linked with higher-level functional capacity in humans (adjusted β −0.031 (P = 0.590) vs. JWGSO-SO−/AWGS-SO−).

    “− 0.031 (P = 0.590), respectively”

    HumansJWGSO-SO−/AWGS-SO+ group vs. JWGSO-SO−/AWGS-SO− reference; multiple regression adjusted for covariatesn = 345

    Overlap between body mass index- and height-adjusted sarcopenic obesity and their association with functional capacity in older adults with diabetes: A study based on the JWGSO consensus

    Endocrine

  2. Sarcopenic obesity was not clearly linked with higher-level functional capacity in humans (adjusted β −0.064 (P = 0.289) vs. JWGSO-SO−/AWGS-SO−).

    “− 0.064 (P = 0.289)”

    Humansboth JWGSO-SO+ and AWGS-SO+ vs. JWGSO-SO−/AWGS-SO− reference; multiple regression adjusted for covariatesn = 345

    Overlap between body mass index- and height-adjusted sarcopenic obesity and their association with functional capacity in older adults with diabetes: A study based on the JWGSO consensus

    Endocrine

  3. Sarcopenic obesity was not clearly linked with higher-level functional capacity in humans (older patients with diabetes).

    “women showed no relationship between sarcopenic obesity and TMIG-IC scores.”

    Humansolder patients with diabetesfemales

    Incidence of sarcopenic obesity in older patients with diabetes and association between sarcopenic obesity and higher-level functional capacity: evaluation based on a consensus statement

    Endocrine journal

  4. Sarcopenic obesity is linked with worse higher-level functional capacity in humans (older patients with diabetes) (adjusted β -2.09 (p = 0.014)).

    “adjusted β coefficient of sarcopenic obesity for scores of the TMIG-IC was -2.09 (p = 0.014) in men.”

    Humansolder patients with diabetesmales

    Incidence of sarcopenic obesity in older patients with diabetes and association between sarcopenic obesity and higher-level functional capacity: evaluation based on a consensus statement

    Endocrine journal

Memory

downin humans2

2 studies
  1. Sarcopenic obesity is linked with worse memory in humans (β = -0.38, 95% CI -0.72 to -0.04).

    “memory (immediate free recall: β ̂ = -0.38; 95% CI, -0.72 to -0.04)”

    Humans2-year follow-upn = 366

    Consensus-Defined Sarcopenic Obesity and a Related Dynapenic Obesity Phenotype in Relation to Early Cognitive Impairment

    Journal of cachexia, sarcopenia and muscle

  2. Sarcopenic obesity is linked with worse memory in humans (SO defined by waist-to-hip-to-height ratio, mean annual change) (adjusted β -0.09 (95% CI -0.14 to -0.05)).

    “associations of SO defined by waist-to-hip-to-height ratio (WHHR) appeared to be the strongest (-0.36 [-0.50 to -0.22], -0.31 [-0.45 to -0.17], -0.09 [-0.14 to -0.05] and -2.70 [-3.81 to -1.59])”

    HumansSO defined by waist-to-hip-to-height ratio, mean annual change

    Associations of Sarcopenia and Sarcopenic Obesity Using Different Obesity Definitions With Memory Decline

    Journal of diabetes

Health-related quality of life

downin humans1no changein humans1−11%

2 studies
  1. Sarcopenic obesity is linked with worse health-related quality of life in humans (compared with non-obese participants) (-10.8%).

    “Health-related quality of life was significantly reduced only in OB men (-10.8%, ES: 1.07, large, p < 0.001) than NOB”

    Humanscompared with non-obese participantsmales

    Sarcopenic Obesity and Sex-Specific Functional Impairment in Older Adults: An Observational Case-Control Study

    Journal of clinical medicine

  2. Sarcopenic obesity was not clearly linked with health-related quality of life in humans after multivariable adjustment.

    “associations with low health-related quality of life or falls were not significant after multivariable adjustment in this cross-sectional analysis”

    Humansafter multivariable adjustmentn = 1,459

    Sarcopenic Obesity in Older Korean Adults: Comparison of 2 Diagnostic Frameworks and Functional Outcomes

    Journal of the American Medical Directors Association

Inflammation

upin humans2

2 studies
  1. Sarcopenic obesity is linked with higher inflammation in humans (COPD).

    “had more pronounced inflammaging according to the neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), and systemic inflammatory index”

    HumansCOPDmales

    The Impact of Sarcopenic Obesity on the Course of Chronic Obstructive Pulmonary Disease in Elderly Men

    Tuberculosis and lung diseases

  2. Sarcopenic obesity increases inflammation in humans.

    “The dual burden of sarcopenia and obesity exacerbates inflammation, insulin resistance, and physical inactivity”

    Review

    Sarcopenic Obesity in Older Adults: A Comprehensive Review of Epidemiology, Risk Factors, Complications, Prevention, and Management

    International Journal of Science and Research (IJSR)

More on Inflammation

Falls

no changein humans2

2 studies
  1. Sarcopenic obesity was not clearly linked with falls in humans after multivariable adjustment; ESPEN-defined group.

    “an independent association with fall risk was not observed in this cross-sectional analysis”

    Humansafter multivariable adjustment; ESPEN-defined groupn = 1,459

    Sarcopenic Obesity in Older Korean Adults: Comparison of 2 Diagnostic Frameworks and Functional Outcomes

    Journal of the American Medical Directors Association

  2. Sarcopenic obesity was not clearly linked with falls in humans.

    “Sarcopenic obesity was not significantly associated with falls in either sex.”

    Humansn = 2,039

    Sex-Specific Associations Between Sarcopenia and Obesity Parameters and Falls in Korean Older Adults: A Cross-Sectional Analysis of the Korean Frailty and Aging Cohort Study

    Medicina (Kaunas, Lithuania)

Weight loss

no changein humans1

1 study
  1. Sarcopenic obesity showed no clear effect on weight loss in humans (older adults with and without sarcopenic obesity).

    “we did not observe any significant differences in the changes between groups from baseline to follow-up”

    Human trialolder adults with and without sarcopenic obesity6-month

    Impact of EASO/ESPEN-Defined Sarcopenic Obesity Following a Technology-Based Weight Loss Intervention

    Calcified tissue international

All 61

Upstream

13

Cortisol

no changein humans1OR 0.607

1 study
  1. Cortisol was not clearly linked with sarcopenic obesity in humans (high hair cortisol levels) (OR: 0.607; 95% CI: 0.162-2.279).

    “or sarcopenic obesity (OR: 0.607; 95% CI: 0.162-2.279).”

    Humanshigh hair cortisol levelsn = 947

    Association Between Hair Cortisol, Sarcopenia, and Sarcopenic Obesity: Results From the ELSA-Brasil Study

    Aging medicine (Milton (N.S.W))

More on Cortisol

Hemoglobin

mediatesin humans1

1 study
  1. Hemoglobin is linked with sarcopenic obesity in humans (indirect effect on the sleep duration–sarcopenic obesity relationship (mediation analysis)) (indirect effect -1.20 × 10−3 (95%CI -2.20 × 10−3 to 3.30 × 10−4); 11.01% of total effect).

    “Hemoglobin had an indirect effect on the relationship between sleep duration and SO, accounting for 11.01% of the total effect variation”

    Humansindirect effect on the sleep duration–sarcopenic obesity relationship (mediation analysis)

    Association between sleep duration and sarcopenic obesity: The mediating role of hemoglobin level

    PloS one

More on Hemoglobin

Hepatic steatosis index

mediatesin humans1

1 study
  1. Hepatic steatosis index is linked with sarcopenic obesity in humans (mediating the association between DI-GM and sarcopenic obesity) (17.8%, p < 0.05).

    “17.8% of the association between DI-GM and SO was mediated by HSI (p < 0.05)”

    Humansmediating the association between DI-GM and sarcopenic obesityn = 3,746

    Association Between Dietary Index for Gut Microbiota and Sarcopenic Obesity in Middle-Aged and Elderly Population: The Mediation Role of Hepatic Steatosis Index

    Food science & nutrition

More on Hepatic steatosis index

Inflammation

mediatesin humans1

1 study
  1. Inflammation is linked with sarcopenic obesity in humans (effect of PM2.5 exposure) (14-26% of the PM2.5 effect).

    “Mediation analysis revealed that systemic inflammation accounted for 14-26% of the effect of PM2.5 exposure on SO development.”

    Humanseffect of PM2.5 exposure

    Air pollution and muscle-fat imbalance: How PM2.5 components and ozone drive sarcopenic obesity through inflammation

    The journal of nutrition, health & aging

More on Inflammation

C-reactive protein

mediatesin humans1

1 study
  1. C-reactive protein is linked with sarcopenic obesity in humans (6.485%).

    “neutrophil-percentage-to-albumin ratio mediated 12.812% and C-reactive protein mediated 6.485% of the associations between E-CDAI and SO”

    Humansn = 4,388

    The association between composite dietary antioxidant index and sarcopenic obesity

    Nutrition & metabolism

More on C-reactive protein

Neutrophil percentage-to-albumin ratio

mediatesin humans1

1 study
  1. Neutrophil percentage-to-albumin ratio is linked with sarcopenic obesity in humans (association between DII and SO) (7.35% mediated).

    “while NPAR mediated 7.35%”

    Humansassociation between DII and SO

    The impact of elevated dietary inflammatory potential on sarcopenic obesity: evidence from two observational studies

    Frontiers in nutrition

More on Neutrophil percentage-to-albumin ratio

C-reactive protein-albumin-lymphocyte index

mediatesin humans1

1 study
  1. C-reactive protein-albumin-lymphocyte index is linked with sarcopenic obesity in humans (association between DII and SO) (39.49% mediated).

    “mediation analysis indicated that CALLY mediated 39.49% of the association between DII and SO”

    Humansassociation between DII and SO

    The impact of elevated dietary inflammatory potential on sarcopenic obesity: evidence from two observational studies

    Frontiers in nutrition

More on C-reactive protein-albumin-lymphocyte index

Non-HDL cholesterol to HDL cholesterol ratio

no changein humans1

1 study
  1. Non-HDL cholesterol to HDL cholesterol ratio was not clearly linked with sarcopenic obesity in humans (above threshold of 3.36).

    “above this threshold, NHHR had no significant effect on sarcopenic obesity prevalence.”

    Humansabove threshold of 3.36n = 8,601

    Association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and Sarcopenic obesity in U.S. adults: a cross-sectional study

    Preventive medicine reports

More on Non-HDL cholesterol to HDL cholesterol ratio

Sex

no changein humans1

1 study
  1. sex showed no clear effect on sarcopenic obesity in humans (elderly men and women) (10% in both men (95% CI: 8%-12%) and women (95% CI: 8%-12%)).

    “A similar result was observed after stratification by sex, with a prevalence of 10% in both men (95% CI: 8%-12%; I2: 97.46%, p<0.001) and women (95% CI: 8%-12%; I2: 98.72%, p<0.001).”

    Reviewelderly men and women

    Prevalence of Sarcopenic Obesity in Elderly Population: A Meta-Analysis

    Current aging science

Triglyceride-glucose index

mediatesin humans1

1 study
  1. Triglyceride-glucose index is linked with sarcopenic obesity in humans (association between SII and SO) (21.36%).

    “TyG was found to mediate 21.36%, 11.78%, and 9.94% of the associations between SII and SO, sarcopenia, and obesity, respectively.”

    Humansassociation between SII and SO

    Association between systemic immune-inflammation index and sarcopenic obesity in middle-aged and elderly Chinese adults: a cross-sectional study and mediation analysis

    Lipids in health and disease

More on Triglyceride-glucose index

All 13

Associations

380

Mortality

upin humans50no changein humans1downin humans1upin reviews1HR 1.2–6.54

53 studies
  1. Sarcopenic obesity is linked with a higher risk of mortality in humans (compared with controls).

    “Over a median follow-up of five years, both groups exhibited significantly higher mortality rates than controls.”

    Humanscompared with controls5 yearsn = 174

    Comparative five-year mortality risk in older adults with sarcopenia and sarcopenic obesity: A retrospective cohort analysis

    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition

  2. Sarcopenic obesity is linked with a higher risk of mortality in humans (late follow-up period) (HR 3.75, 95% CI 1.66-8.50, p = 0.002).

    “JWGSO-defined sarcopenic obesity was not significantly associated with mortality in the early follow-up but was linked to increased mortality risk in the late period (HR 3.75, 95% CI 1.66-8.50, p = 0.002).”

    Humanslate follow-up periodn = 736

    Clinical characteristics and survival in sarcopenic obesity defined by the Japanese working group on sarcopenic obesity criteria versus existing definitions in older adults: findings from the Otassha study

    International journal of obesity (2005)

  3. Sarcopenic obesity is linked with a higher risk of mortality in humans following major abdominal cancer surgery (HR 6.44, 95% CI 2.45-16.92, p < 0.001).

    “SO patients experienced significantly increased short-term mortality at 30 days (HR 6.44, 95% CI 2.45-16.92, p < 0.001∗)”

    Humansfollowing major abdominal cancer surgery

    Impact of sarcopenic obesity on outcomes following major abdominal cancer surgery: A population-based observational study

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

  4. Sarcopenic obesity is linked with a higher risk of mortality in humans (esophageal cancer undergoing curative treatment) (HR 2.47, 95% CI 1.39–4.37, p = 0.002).

    “Only the combination of both, sarcopenic obesity was significantly associated in multivariable analysis (HR 2.47, 95 %CI 1.39; 4.37, p = 0.002)”

    Humansesophageal cancer undergoing curative treatmentn = 145

    Prognostic relevance of CT-defined body composition in esophageal cancer patients undergoing curative treatment

    Surgical oncology

  5. Sarcopenic obesity is linked with a higher risk of mortality in cancer patients (adjusted HR 1.368, 95% CI 1.107-1.690).

    “cancer patients with SO were significantly associated with a higher risk of all-cause mortality (adjusted HR 1.368, 95%CI 1.107-1.690) compared with individuals without SO”

    Humansin cancer patientsn = 1,432

    Exploring Sarcopenic Obesity in the Cancer Setting: Insights from the National Health and Nutrition Examination Survey on Prognosis and Predictors Using Machine Learning

    Bioengineering (Basel, Switzerland)

  6. Sarcopenic obesity is linked with a higher risk of mortality in humans (hospitalized older adults) (15.1% vs. 9.3%, p = 0.03).

    “The SO group had higher mortality (15.1% vs. 9.3%, p = 0.03).”

    Humanshospitalized older adultsn = 364

    Sarcopenic obesity is linked to worse clinical outcomes than sarcopenia or obesity alone in hospitalized older adults

    BMC geriatrics

  7. Sarcopenic obesity is linked with a higher risk of mortality in humans (hip fracture surgery) (HR: 2.68, 95% CI: 1.10-2.57, p = .016).

    “Sarcopenic obesity further increased mortality risk (HR: 2.68, 95% CI: 1.10-2.57, p = .016)”

    Humanship fracture surgeryn = 311

    Sarcopenia and sarcopenic obesity: Their association with postoperative outcomes in patients with hip fractures

    Journal of hospital medicine

  8. Sarcopenic obesity is linked with a higher risk of mortality in humans (sarcopenic obesity) (p = 0.002).

    “Additionally, this group exhibited reduced handgrip strength and elevated mortality rates (p = 0.002).”

    Humanssarcopenic obesityn = 364

    Sarcopenic Obesity in Older Adults: A More Dependent, Frail, and Even Fatal Condition than Sarcopenia or Obesity Alone. A Retrospective Cross-Sectional Study

    Preprints.orgPreprint

  9. Sarcopenic obesity predicts mortality in humans (compared to patients with non-sarcopenic non-obesity phenotype) (HR: 2.78, 95% CI 1.57-4.94; P = 0.001).

    “all-cause mortality (hazard ratio[HR]: 2.78, 95% CI 1.57-4.94; P = 0.001)”

    Humanscompared to patients with non-sarcopenic non-obesity phenotype3 yearsn = 487

    The association between sarcopenic obesity, sarcopenia and functional dependence, malnutrition, and mortality: the phenomenon of obesity paradox in sarcopenic obesity

    European geriatric medicine

  10. Sarcopenic obesity is linked with a higher risk of mortality in humans (palliative-intent cancer) (HR 5.5, 95% CI 1.9-17).

    “and 88 % vs. 47 % in group without and with 'high VATI+low SMI', respectively (5.5; 1.9-17)”

    Humanspalliative-intent cancern = 58

    Computed tomography-determined high visceral adipose tissue and sarcopenic obesity and their associations with survival in vulnerable or frail older adults with cancer considered for systemic anticancer treatment

    Journal of geriatric oncology

All 53

Cardiovascular disease

upin humans18no changein humans1HR 1.05–6.02

19 studies
  1. Sarcopenic obesity is associated with cardiovascular disease in humans (Older Chinese adults; fully adjusted Cox models) (HR 1.39, 95% CI 1.09–1.77).

    “SO was associated with a higher hazard of incident CVD (HR = 1.39, 95% CI 1.09–1.77; P = 0.008).”

    HumansOlder Chinese adults; fully adjusted Cox modelsn = 5,971

    Heterogeneous obesity phenotypes and late-life health in China

    BMC geriatrics

  2. Sarcopenic obesity is linked with a higher risk of cardiovascular disease in humans (HR 2.07, 95% CI 1.76–2.43).

    “participants with SO faced a significantly higher risk of incident CVD (HR: 2.07, 95% CI 1.76–2.43) compared to the Normal group”

    Humans

    Sarcopenic Obesity Accelerates the Progression of Cardiovascular-Kidney-Metabolic Syndrome: A Longitudinal Discovery and Cross-Sectional Validation Study

    Research SquarePreprint

  3. Sarcopenic obesity is associated with cardiovascular disease in humans (6.4 times).

    “individuals with SO were 6.4 times more likely to have cardiovascular comorbidity in comparison to the control group.”

    Humansn = 419

    Geriatric and cardiometabolic syndromes in older adults with sarcopenic obesity: a comparative cross-sectional study with sarcopenia and obesity

    BMC geriatrics

  4. Sarcopenic obesity is associated with cardiovascular disease in humans (sarcopenic obesity alone) (HR 1.05, 95% CI 0.94-1.17).

    “1.05 (95% CI: 0.94-1.17) for sarcopenic obesity alone”

    Humanssarcopenic obesity alone9 yearsn = 10,478

    Synergistic effects of diabetes and sarcopenic obesity on cardiovascular disease risk in middle-aged and elderly Chinese adults: a large-scale prospective cohort study

    Aging clinical and experimental research

  5. Sarcopenic obesity is linked with a higher risk of cardiovascular disease in humans (HR = 1.39, 95% CI = 1.16-1.67).

    “Sarcopenic obesity were related to increased risks of CVD (HR = 1.39; 95% CI = 1.16-1.67)”

    Humans

    Associations between sarcopenic obesity and risk of cardiovascular disease: A population-based cohort study among middle-aged and older adults using the CHARLS

    Clinical nutrition (Edinburgh, Scotland)

  6. Sarcopenic obesity is linked with a higher risk of cardiovascular disease in subjects with NAFLD (training aOR 5.20, validation aOR 3.71).

    “CVD (training: aOR, 5.20; validation: aOR, 3.71) than subjects without SO (all P < .001)”

    Humansin subjects with NAFLD

    Risk Stratification for Sarcopenic Obesity in Subjects With Nonalcoholic Fatty Liver Disease

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

  7. Sarcopenic obesity is linked with a higher risk of cardiovascular disease in humans (elderly patients with T2DM, SO classified using BF%) (HR = 6.02, 95% CI = 1.56-23.15).

    “SO classified using BF% was significantly associated with the primary endpoint [hazard ratio (HR) = 2.94, 95% CI = 1.25-6.92] and incident CVD (HR = 6.02, 95% CI = 1.56-23.15)”

    Humanselderly patients with T2DM, SO classified using BF%3.46 ± 1.15 yearsn = 386

    Sarcopenic obesity predicts negative health outcomes among older patients with type 2 diabetes: The Ageing and Body Composition of Diabetes (ABCD) cohort study

    Clinical nutrition (Edinburgh, Scotland)

  8. Sarcopenic obesity is associated with cardiovascular disease in humans.

    “cardiovascular disease (three studies), metabolic syndrome (one study)”

    Review

    Adverse outcomes of sarcopenic obesity in older adults: a scoping review

    Frontiers in nutrition

  9. Sarcopenic obesity raises the risk of cardiovascular disease in humans.

    “Sarcopenic obesity has been associated with an increased risk of cardiovascular diseases, type 2 diabetes, frailty, disability, and mortality.”

    Review

    WHY SARCOPENIC OBESITY IS THE STRATEGIC INTERSECTION? – A NARRATIVE REVIEW

    International Journal of Innovative Technologies in Social Science

  10. Sarcopenic obesity is associated with cardiovascular disease in humans.

    “strong association with metabolic disorders, cardiovascular diseases, frailty, disability, and increased mortality.”

    Review

    Sarcopenic Obesity in Older Adults: A Comprehensive Review of Epidemiology, Risk Factors, Complications, Prevention, and Management

    International Journal of Science and Research (IJSR)

All 19

More on Cardiovascular disease

Frailty

upin humans17OR 1.7–6.4

17 studies
  1. Sarcopenic obesity is associated with frailty in humans (OR 4.23 (95% CI 1.42–12.55)).

    “4.23 (1.42–12.55) for sarcopenic obesity”

    Humansfemalesn = 115

    Prevalence and Clinical Associations of Osteosarcopenic Obesity and Frailty in Mexican Elderly Women: A Cross-Sectional Pilot Study

    Journal of Gerontology and Geriatrics

  2. Sarcopenic obesity is associated with frailty in humans (categorical definition based on ESPEN-EASO-aligned criteria).

    “Both categorical sarcopenic obesity and the SOPi were independently associated with frailty”

    Humanscategorical definition based on ESPEN-EASO-aligned criteria

    Bioelectrical impedance analysis-based Sarcopenic Obesity Phenotype Index versus sarcopenic obesity: associations with frailty, falls, and osteoporosis in community-dwelling older adults

    Nutrition (Burbank, Los Angeles County, Calif.)

  3. Sarcopenic obesity is associated with frailty in humans (fully adjusted (Model 2)) (OR 2.51, 95% CI 1.21-5.24).

    “SO (OR, 2.51; 95% CI, 1.21-5.24) were associated with increased odds of prefrailty/frailty.”

    Humansfully adjusted (Model 2)n = 481

    Sarcopenic obesity and sarcopenia in relation to frailty, independent of locomotive syndrome: the DETECt-L cross-sectional study

    Osteoporosis and sarcopenia

  4. Sarcopenic obesity is linked with a higher risk of frailty in humans (community-dwelling older adults) (OR 4.71).

    “SO was significantly associated with frailty (OR 4.71)”

    Humanscommunity-dwelling older adultsn = 202

    The Impact of Sarcopenic Obesity on Frailty, Cognition, and Function in Community-Dwelling Older Adults

    Journal of frailty, sarcopenia and falls

  5. Sarcopenic obesity is associated with frailty in humans (patients with obesity) (OR 3.30, 95% CI 1.38-7.92).

    “SO, diagnosed by BIA and US, was independently associated with frailty regardless of confounding factors (odds ratio: 3.30, 95% confidence interval [CI]: 1.38-7.92”

    Humanspatients with obesityn = 142

    Sarcopenic obesity is independently associated with frailty in geriatric outpatients: A cross-sectional study from university hospital

    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition

  6. Sarcopenic obesity is linked with a higher risk of frailty in humans (longitudinal analysis) (OR 4.27 (95% CI 2.05-8.93)).

    “SO [FP, OR (95% confidence interval-CI): 4.27 (2.05, 8.93); FTS5, OR (95% CI): 6.14 (3.58, 10.51), p-value < .001]”

    Humanslongitudinal analysisn = 1,538

    Sarcopenia, Obesity, or Both. What is the dominant Variable of the Associated Risks of Sarcopenic Obesity?

    Innovation in aging

  7. Sarcopenic obesity is associated with frailty in humans (cross-sectional prevalence) (OR 1.70 (95% CI 1.33-2.16)).

    “SO was associated with the prevalence of frailty by both the EASO's [OR(95%CI): FFP: 1.70 (1.33-2.16)”

    Humanscross-sectional prevalencen = 1,559

    The Performance and Associated Risks of the Criteria for Sarcopenic Obesity Proposed by the European Association for the Study of Obesity in a Geriatric Population

    Nutrients

  8. Sarcopenic obesity is associated with frailty in humans (B 0.074, 95% CI 0.05-0.1, p < 0.001).

    “SO (B 0.074, 95% C.I. 0.05-0.1, p < 0.001) and pre-sarcopenia (without obesity B 0.03, 95% C.I, 0.007-0.044, p < 0.001, with obesity B 0.11, 95% C.I. 0.05-0.16, p < 0.001) were associated with frailty.”

    Humans

    Sarcopenic obesity and pre-sarcopenia contribute to frailty in community-dwelling Italian older people: data from the FRASNET study

    BMC geriatrics

  9. Sarcopenic obesity is associated with frailty in humans (locomotive syndrome stage 1) (OR 4.25, 95% CI 1.34 to 13.5).

    “The odds ratios for frailty risk compared to normal were 3.97 (95% confidence interval (CI): 1.51 to 10.4), 1.71 (95% CI: 0.55 to 5.39), and 4.25 (95% CI: 1.34 to 13.5) for sarcopenia (RT2), obesity, and sarcopenic obesity subtypes, respectively”

    Humanslocomotive syndrome stage 1femalesn = 158

    Association Between Sarcopenic Obesity and Frailty Risk in Community-Dwelling Older Women With Locomotive Syndrome: A Cross-Sectional Survey

    Cureus

  10. Sarcopenic obesity is linked with a higher risk of frailty in older adults with diabetes.

    “SO was further linked to increased risk of falls, frailty, and various levels of activities of daily living (ADL) and instrumental activities of daily living (IADL) disabilities”

    Humansin older adults with diabetes

    Sarcopenic Obesity Burden, Determinants, and Association With Risk of Frailty, Falls, and Functional Impairment in Older Adults With Diabetes: A Propensity Score Matching Analysis

    Cureus

All 17

Hypertension

upin humans13OR 1.49–3.67

13 studies
  1. Hypertension is linked with a higher risk of sarcopenic obesity in fully adjusted models for 1-year SO deterioration (OR = 3.67, 95% CI: 1.26-10.66).

    “In fully adjusted models, hypertension (OR = 3.67, 95% CI: 1.26-10.66) and diabetes (OR = 4.01, 95% CI: 1.07-15.12) were independent predictors of SO deterioration.”

    Humansin fully adjusted models for 1-year SO deterioration1 yearn = 1,048

    Prevalence and one-year transition of sarcopenic obesity in Taiwan - using new definition from Asia-Oceania sarcopenic obesity consensus

    Journal of the Formosan Medical Association = Taiwan yi zhi

  2. Sarcopenic obesity is associated with hypertension in humans (67.74% vs others).

    “SO patients had a significantly higher burden of comorbidities, including hypertension (67.74%), diabetes mellitus (70.97%), and hypothyroidism (35.48%)”

    Humansn = 419

    Geriatric and cardiometabolic syndromes in older adults with sarcopenic obesity: a comparative cross-sectional study with sarcopenia and obesity

    BMC geriatrics

  3. Sarcopenic obesity is associated with hypertension in humans.

    “Sarcopenic obesity was significantly associated with hypertension among men and women.”

    Humans

    Prevalence and Related Factors of Suspected Sarcopenia and Sarcopenic Obesity in Community-Dwelling Older Adults

    Asian nursing research

  4. Sarcopenic obesity is associated with hypertension in humans (diabetic outpatients).

    “hypertension, elevated HbA1c, and lower quality of life were linked to HGS-based SO.”

    Humansdiabetic outpatientsn = 276

    Screening Risk of Sarcopenic Obesity Using SARC-F and Handgrip Strength in Outpatients with Diabetes

    Metabolic syndrome and related disorders

  5. Hypertension is linked with a higher risk of sarcopenic obesity in humans (hospitalized older adults) (OR = 2.094, p = 0.007).

    “Independent predictors of SO included older age (OR = 1.064, p = 0.002), female gender (OR = 3.574, p < 0.001), hypertension (OR = 2.094, p = 0.007), and diabetes mellitus (OR = 3.342, p < 0.001).”

    Humanshospitalized older adultsn = 364

    Sarcopenic obesity is linked to worse clinical outcomes than sarcopenia or obesity alone in hospitalized older adults

    BMC geriatrics

  6. Sarcopenic obesity is linked with a higher risk of hypertension in humans (HR 3.66, 95% CI 2.98-4.50).

    “and 3.66 times (95% CI, 2.98-4.50) higher risks of developing hypertension, respectively.”

    Humans5 yearsmales

    Obesity, Sarcopenia, Sarcopenic Obesity, and Hypertension: Mediating Role of Inflammation and Insulin Resistance

    The journals of gerontology. Series A, Biological sciences and medical sciences

  7. Hypertension is linked with a higher risk of sarcopenic obesity in humans (sarcopenic obesity) (β = 0.396, p = 0.001).

    “Both hypertension (β = 0.396, p = 0.001) and diabetes mellitus (β = 3.074, p < 0.001) were identified as significant risk factors for SO”

    Humanssarcopenic obesityn = 364

    Sarcopenic Obesity in Older Adults: A More Dependent, Frail, and Even Fatal Condition than Sarcopenia or Obesity Alone. A Retrospective Cross-Sectional Study

    Preprints.orgPreprint

  8. Sarcopenic obesity is linked with a higher risk of hypertension in humans (community population) (HR 1.61 (95% CI 1.09–2.37), p = 0.017).

    “sarcopenic obesity were associated with hypertension; hazard ratios (HRs) and 95% confidence intervals (CIs) were 1.67 (1.43 ~ 1.96), p < 0.001, and 1.61 (1.09 ~ 2.37), p = 0.017”

    Humanscommunity population7 yearsn = 7,301

    Sarcopenia is not associated with hypertension, but sarcopenic obesity increases risk of hypertension: a 7-year cohort study

    Frontiers in public health

  9. Sarcopenic obesity is associated with hypertension in adults aged >= 60 years (56.04% vs 38.93%; P < 0.01).

    “prevalence of cardiovascular disease (15.38% vs 6.59%; P < 0.01), hypertension (56.04% vs 38.93%; P < 0.01), and stroke (7.69% vs 2.25%; P < 0.01) was also significantly higher in the SO group”

    Humansin adults aged >= 60 years

    Prevalence of sarcopenic obesity among older adults in communities of China: A multicenter, cross-sectional study

    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition

  10. Sarcopenic obesity is associated with hypertension in humans (sarcopenic obesity).

    “revealed that the S-O group had more patients with hypertension, diabetes, osteopenia, and metabolic syndrome.”

    Humanssarcopenic obesityfemales

    Correlation of Sarcopenic Obesity on Various Cardiometabolic Risk Factors and Fracture Risk in Mid-Aged Korean Women

    Journal of menopausal medicine

All 13

More on Hypertension

Physical activity

downin humans8upin humans4OR 0.44–3.96

12 studies
  1. Physical activity is associated with sarcopenic obesity in humans (Mexican adults; multivariable model) (OR = 0.996, P = .020).

    “protective factors included metformin use (odds ratio [OR] = 0.181), P = .005) and increased physical activity (OR = 0.996, P = .020).”

    HumansMexican adults; multivariable model

    Risk Factors for Sarcopenic Obesity in Adults: A Case-Control Study Using Bioelectrical Impedance Analysis

    AACE endocrinology and diabetes

  2. Physical activity is associated with sarcopenic obesity in obese T2DM patients.

    “SO was significantly associated with older age, low physical activity, poor glycemic control, insulin use, and the presence of diabetes complications.”

    Humansin obese T2DM patientsn = 151

    Sarcopenic Obesity in Indian Adults with Type 2 Diabetes Mellitus: Prevalence and Associated Risk Factors

    Indian journal of endocrinology and metabolism

  3. Sarcopenic obesity is associated with physical activity in bariatric surgery candidates.

    “Those with SO had a lower BMD and PA levels.”

    Humansin bariatric surgery candidatesn = 109

    Preoperative assessment of sarcopenia and osteosarcopenia prevalence in bariatric surgery candidates over 60

    Clinical nutrition ESPEN

  4. Physical activity is linked with a lower risk of sarcopenic obesity in humans.

    “Decreased odds of SO were consistently associated with better PA and SB trajectories.”

    Humansn = 1,484

    Sarcopenic obesity is associated with long-term trajectories of physical activity and sedentary behavior

    Experimental gerontology

  5. Physical activity is associated with sarcopenic obesity in Korean elderly.

    “Sarcopenic obesity was associated with living alone, high hsCRP, stress, and low physical activity.”

    Humansin Korean elderly

    FACTORS IN ABDOMINAL OBESITY, SARCOPENIA, AND SARCOPENIC OBESITY AMONG KOREAN ELDERLY: KNHANES 2022

    GSA 2024 abstract

  6. Physical activity is associated with sarcopenic obesity in humans (OR 3.96, 95% CI 1.32-11.8).

    “Sarcopenic obesity was associated with the general physical activity level (odds ratio, 3.96; 95% CI, 1.32-11.8)”

    Humansfemalesn = 317

    Prevalence of sarcopenic obesity in women and its association with level of independent physical activity combined with sedentary behavior

    Menopause (New York, N.Y.)

  7. Physical activity is associated with sarcopenic obesity in humans (> 3032 kcal/week for men and 2730 kcal/week for women).

    “A total physical activity energy expenditure of > 3032 kcal/week (433 kcal/day) for men and 2730 kcal/week (390 kcal/day) for women was associated with a reduced prevalence of SO.”

    Humans> 3032 kcal/week (433 kcal/day) for men and 2730 kcal/week (390 kcal/day) for womenn = 2,071

    The Impact of the Physical Activity Level on Sarcopenic Obesity in Community-Dwelling Older Adults

    Healthcare (Basel, Switzerland)

  8. Physical activity is linked with a lower risk of sarcopenic obesity in humans.

    “The high activity group had a significantly lower prevalence of SO than the non-high activity (low and moderate activity) group.”

    Humansn = 2,071

    The Impact of the Physical Activity Level on Sarcopenic Obesity in Community-Dwelling Older Adults

    Healthcare (Basel, Switzerland)

  9. Physical activity is linked with a lower risk of sarcopenic obesity in humans.

    “The likelihood of central obesity and sarcopenic obesity decreased in groups with recommended PA levels, regardless of whether energy intake met or did not meet the average requirement.”

    Humans

    The effect of combining nutrient intake and physical activity levels on central obesity, sarcopenia, and sarcopenic obesity: a population-based cross-sectional study in South Korea

    BMC geriatrics

  10. Physical activity is linked with a higher risk of sarcopenic obesity in participants with serum 25(OH)D < 20 ng/ml.

    “Low PA was significantly associated with obesity, sarcopenia, and sarcopenic obesity only in participants with serum 25(OH)D < 20 ng/ml.”

    Humansin participants with serum 25(OH)D < 20 ng/mln = 3,713

    Sex differences in the association of physical activity levels and vitamin D with obesity, sarcopenia, and sarcopenic obesity: a cross-sectional study

    BMC geriatrics

All 13

More on Physical activity

Diabetes mellitus

upin humans10OR 1.94–4.01

10 studies
  1. Diabetes mellitus is linked with a higher risk of sarcopenic obesity in fully adjusted models for 1-year SO deterioration (OR = 4.01, 95% CI: 1.07-15.12).

    “In fully adjusted models, hypertension (OR = 3.67, 95% CI: 1.26-10.66) and diabetes (OR = 4.01, 95% CI: 1.07-15.12) were independent predictors of SO deterioration.”

    Humansin fully adjusted models for 1-year SO deterioration1 yearn = 1,048

    Prevalence and one-year transition of sarcopenic obesity in Taiwan - using new definition from Asia-Oceania sarcopenic obesity consensus

    Journal of the Formosan Medical Association = Taiwan yi zhi

  2. Diabetes mellitus is linked with a higher risk of sarcopenic obesity in humans (hospitalized older adults) (OR = 3.342, p < 0.001).

    “Independent predictors of SO included older age (OR = 1.064, p = 0.002), female gender (OR = 3.574, p < 0.001), hypertension (OR = 2.094, p = 0.007), and diabetes mellitus (OR = 3.342, p < 0.001).”

    Humanshospitalized older adultsn = 364

    Sarcopenic obesity is linked to worse clinical outcomes than sarcopenia or obesity alone in hospitalized older adults

    BMC geriatrics

  3. Diabetes mellitus is linked with a higher risk of sarcopenic obesity in humans (sarcopenic obesity).

    “diabetes mellitus (β = 3.074, p < 0.001) were identified as significant risk factors for SO, with diabetes increasing the risk approximately threefold.”

    Humanssarcopenic obesityn = 364

    Sarcopenic Obesity in Older Adults: A More Dependent, Frail, and Even Fatal Condition than Sarcopenia or Obesity Alone. A Retrospective Cross-Sectional Study

    Preprints.orgPreprint

  4. Sarcopenic obesity is associated with diabetes mellitus in humans (OR 1.94, 95% CI 1.81-2, p < 0.001).

    “those with sarcopenic obesity by BMI had significantly elevated odds (1.94, 95 % CI 1.81-2, p < 0.001) for self-reported diabetes”

    Humans

    Possible sarcopenia, sarcopenic obesity phenotypes and their association with diabetes: Evidence from LASI wave-1 (2017-18)

    Diabetes & metabolic syndrome

  5. Sarcopenic obesity is linked with a higher risk of diabetes mellitus in humans (OR = 2.21, 95 % CI: 1.72-2.84).

    “Participants with sarcopenia obesity exhibit a higher risk of diabetes than those with obesity or sarcopenia alone (CNHS, OR = 2.21, 95 %CI:1.72-2.84”

    Humans

    Associations of muscle mass, strength, and quality with diabetes and the mediating role of inflammation in two National surveys from China and the United states

    Diabetes research and clinical practice

  6. Sarcopenic obesity is associated with diabetes mellitus in humans (compared to obesity).

    “Sarcopenic obesity showed a higher prevalence of diabetes and lower HDL cholesterol levels compared to obesity.”

    Humanscompared to obesity

    Sex-Specific Effects of Dietary Factors on Sarcopenic Obesity in Korean Elderly: A Nationwide Cross-Sectional Study

    Nutrients

  7. Diabetes mellitus is associated with sarcopenic obesity in humans (13.3% vs. 6.5%).

    “obesity and sarcopenic obesity were more prevalent among diabetic patients in a nursing home”

    Humansn = 397

    The prevalence of sarcopenic obesity and its relationship with type 2 diabetes in a nursing home

    European review for medical and pharmacological sciences

  8. Diabetes mellitus is associated with sarcopenic obesity in humans (chronic hemodialysis patients) (OR 3.495, 95% CI 1.683-7.255).

    “diabetes was significantly and independently associated with sarcopenic obesity (odds ratio 3.495, 95% confidence interval 1.683-7.255, P = .0008)”

    Humanschronic hemodialysis patientsn = 308

    Significant Association of Diabetes With Mortality of Chronic Hemodialysis Patients, Independent of the Presence of Obesity, Sarcopenia, and Sarcopenic Obesity

    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation

  9. Diabetes mellitus is associated with sarcopenic obesity in humans (adults with diabetes) (24% (95% CI: 19-29%)).

    “The pooled prevalence of SO among adults with diabetes was 24% (95% confidence interval: 19-29%), with substantial heterogeneity.”

    Reviewadults with diabetes

    Prevalence of sarcopenic obesity in adult patients with diabetes and associated factors: a systematic review and meta-analysis

    Frontiers in nutrition

  10. Diabetes mellitus is associated with sarcopenic obesity in humans.

    “diabetes, hypertension, osteoporosis, depression, mild cognitive impairment, a fall history, frailty, and metabolic syndrome among the disease factors”

    Review

    Risk factors associated with sarcopenic obesity in older adults: A meta-analysis and systematic review

    Clinical nutrition ESPEN

More on Diabetes mellitus

Falls

upin humans10HR 1.25–3.98

10 studies
  1. Sarcopenic obesity is associated with falls in the type 2 diabetes group, compared with the robust group.

    “In the T2D group, sarcopenic obesity was associated with lower physical QOL, reduced physical activity, slow gait speed, and a high incidence of falls compared with the robust group.”

    Humansin the type 2 diabetes group, compared with the robust groupn = 527

    Clinical characteristics of Sarcopenic obesity in Japanese people with type 2 diabetes: A post hoc analysis of the sub-cohort iDIAMOND study

    Journal of diabetes investigation

  2. Sarcopenic obesity is linked with a higher risk of falls in early-onset type 2 diabetes patients, characterized by visceral fat area (HR 3.98, 95% CI 2.57-6.16).

    “EOT2D patients with sarcopenic obesity, particularly characterized by visceral fat area (VFA), demonstrated a substantially higher fall risk (HREOT2D+SO-VFA = 3.98; 95% CI: 2.57-6.16)”

    Humansin early-onset type 2 diabetes patients, characterized by visceral fat area

    Sarcopenic obesity increases the risk of falls in early-onset type 2 diabetes

    Journal of endocrinological investigation

  3. Sarcopenic obesity is associated with falls in humans (stable schizophrenia) (adjusted OR = 2.889, p=0.002).

    “SO was significantly associated with increased fall risk (adjusted OR = 2.889, p=0.002)”

    Humansstable schizophrenian = 490

    Ultrasonographic assessment of thenar muscles for diagnosing sarcopenic obesity in patients with schizophrenia

    Frontiers in psychiatry

  4. Sarcopenic obesity is linked with a higher risk of falls in humans (unadjusted longitudinal analysis) (HR 2.78 (95% CI 2.03–3.80), P < 0.01).

    “In the longitudinal analysis (2015-2020), the SO group [HR (95%CI): 2.78 (2.03 ~ 3.80), P < 0.01] had a significantly increased risk of falls.”

    Humansunadjusted longitudinal analysis

    Sarcopenic obesity and risk of falls: findings in Middle-aged and older Chinese population from CHARLS

    Aging clinical and experimental research

  5. Sarcopenic obesity is associated with falls in humans (diabetic outpatients).

    “Falls, depressive symptoms, and reduced quality of life were associated with SARC-F-based SO”

    Humansdiabetic outpatientsn = 276

    Screening Risk of Sarcopenic Obesity Using SARC-F and Handgrip Strength in Outpatients with Diabetes

    Metabolic syndrome and related disorders

  6. Sarcopenic obesity is linked with a higher risk of falls in humans (HR = 1.25; 95% CI: 1.00-1.56).

    “those with sarcopenic obesity had a significantly higher risk of falls (HR = 1.25; 95% CI: 1.00-1.56; P = 0.048)”

    Humans

    Associations between sarcopenic obesity and risk of falls: a population-based cohort study among middle-aged and older adults using the CHARLS

    BMC public health

  7. Sarcopenic obesity is linked with a higher risk of falls in humans after adjusting for confounders (OR 1.61, 95% CI 1.08–2.40).

    “only SOESPEN was significantly associated with falls (odds ratios [OR] 1.61, 95 % confidence interval [CI] 1.08 to 2.40)”

    Humansafter adjusting for confoundersn = 1,353

    Sarcopenic obesity and falls in older adults: A validation study of ESPEN/EASO criteria and modifications in Western China communities

    Archives of gerontology and geriatrics

  8. Sarcopenic obesity is linked with a higher risk of falls in older adults with diabetes.

    “SO was further linked to increased risk of falls, frailty, and various levels of activities of daily living (ADL) and instrumental activities of daily living (IADL) disabilities”

    Humansin older adults with diabetes

    Sarcopenic Obesity Burden, Determinants, and Association With Risk of Frailty, Falls, and Functional Impairment in Older Adults With Diabetes: A Propensity Score Matching Analysis

    Cureus

  9. Sarcopenic obesity is linked with a higher risk of falls in humans (compared with men with neither sarcopenia nor obesity) (incident rate ratio: 1.59, 95% CI: 1.03-2.44).

    “higher 12-month incident falls rates (incident rate ratio: 1.59, 95% CI: 1.03-2.44) than men with neither sarcopenia nor obesity.”

    Humanscompared with men with neither sarcopenia nor obesity12 monthsmalesn = 1,416

    Sarcopenia prevalence and functional outcomes in older men with obesity: Comparing the use of the EWGSOP2 sarcopenia versus ESPEN-EASO sarcopenic obesity consensus definitions

    Clinical nutrition (Edinburgh, Scotland)

  10. Sarcopenic obesity raises the risk of falls in humans.

    “Sarcopenic obesity is becoming increasingly prevalent among older adults and may contribute to greater risk of functional decline, falls, fractures and mortality than sarcopenia or obesity alone.”

    Review

    Sarcopenic obesity: pathogenesis, epidemiology and management in older adults

    Expert review of endocrinology & metabolism

Cognitive impairment

upin humans8OR 1.47–3.56

8 studies
  1. Sarcopenic obesity is linked with a higher risk of cognitive impairment in older adults with type 2 diabetes (adjusted OR = 2.84, p = 0.005).

    “Participants with SO had significantly higher odds of CI than those without SO (adjusted OR = 2.84, p = 0.005).”

    Humansin older adults with type 2 diabetesn = 235

    Association between sarcopenic obesity and cognitive impairment among taiwanese older adults with type 2 diabetes mellitus: A cross-sectional study

    Geriatric nursing (New York, N.Y.)

  2. Sarcopenic obesity is linked with a higher risk of cognitive impairment in humans (both BMI-defined and WC-defined sarcopenic obesity phenotypes).

    “both SO phenotypes were associated with a higher risk of depressive symptoms and cognitive impairment.”

    Humansboth BMI-defined and WC-defined sarcopenic obesity phenotypes

    Comparative analysis of sarcopenic obesity detection and associated mental-cognitive outcomes in community-dwelling older adults: impact of using body mass index versus waist circumference

    BMC geriatrics

  3. Sarcopenic obesity is linked with a higher risk of cognitive impairment in humans (community-dwelling older adults) (OR 3.56).

    “SO was also linked to cognitive impairment (OR 3.56).”

    Humanscommunity-dwelling older adultsn = 202

    The Impact of Sarcopenic Obesity on Frailty, Cognition, and Function in Community-Dwelling Older Adults

    Journal of frailty, sarcopenia and falls

  4. Sarcopenic obesity is associated with cognitive impairment in humans (at diagnosis I) (OR 2.3, 95% CI 1.4-3.8, P = 0.007).

    “Significant associations between SO and cognitive impairment were observed in individuals aged 60-85 at diagnosis I (OR: 2.3, 95%CI 1.4-3.8, P = 0.007)”

    Humansat diagnosis In = 2,356

    Application of a new definition of sarcopenic obesity in middle-aged and older adults and association with cognitive function: Findings from the National Health and Nutrition Examination Survey 1999-2002

    Clinical nutrition ESPEN

  5. Sarcopenic obesity is associated with cognitive impairment in humans (adjusted for age, sex and marital status) (OR 3.03 (CI 1.51-6.06)).

    “cognitive impairment (3.03 [CI 1.51-6.06])”

    Humansadjusted for age, sex and marital status

    Sarcopenic obesity using the ESPEN and EASO consensus statement criteria of 2022 - Results from the German KORA-Age study

    Obesity research & clinical practice

  6. Sarcopenic obesity is linked with a higher risk of cognitive impairment in humans (patients requiring maintenance hemodialysis) (OR 1.47, 95% CI 1.11-1.96).

    “The association between SO and CI was weakened but remained statistically significant after adjusting for age, sex, and educational status (odds ratio, 1.47; 95% CI, 1.11-1.96).”

    Humanspatients requiring maintenance hemodialysis

    Associations of sarcopenic obesity vs either sarcopenia or obesity alone with cognitive impairment risk in patients requiring maintenance hemodialysis

    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition

  7. Sarcopenic obesity raises the risk of cognitive impairment in humans (compared with non-SO) (OR 3.46, 95% CI 2.24-5.32).

    “compared with non-SO, SO increased the prevalence of cognitive impairment (k = 3; odds ratio [OR] = 3.46; 95% CI: 2.24-5.32; high certainty of evidence)”

    Reviewcompared with non-SO

    Sarcopenic obesity and health outcomes: An umbrella review of systematic reviews with meta-analysis

    Journal of cachexia, sarcopenia and muscle

  8. Sarcopenic obesity is associated with cognitive impairment in humans.

    “sarcopenia and sarcopenic obesity have been reported to be associated with cognitive impairment”

    Review

    Recent Updates on Associations among Various Obesity Metrics and Cognitive Impairment: from Body Mass Index to Sarcopenic Obesity

    Journal of obesity & metabolic syndrome

More on Cognitive impairment

Exercise

downin humans4upin humans2downin reviews1OR 0.42–2

7 studies
  1. Exercise is linked with a lower risk of sarcopenic obesity in humans during menopausal transition (OR 0.42, 95% CI 0.25-0.71).

    “somewhat active women had lower risk of peri-menopausal onset (odds ratio 0.42; 95% confidence interval 0.25-0.71)”

    Humansduring menopausal transitionsomewhat activefemalesn = 1,450

    Activity links to lower sarcopenic obesity risk across menopause

    Maturitas

  2. Exercise is linked with a lower risk of sarcopenic obesity in age/sex-adjusted models (OR = 0.46).

    “Conversely, regular exercise (OR = 0.46 in age/sex-adjusted models) and higher education were protective factors promoting improvement.”

    Humansin age/sex-adjusted models1 yearn = 1,048

    Prevalence and one-year transition of sarcopenic obesity in Taiwan - using new definition from Asia-Oceania sarcopenic obesity consensus

    Journal of the Formosan Medical Association = Taiwan yi zhi

  3. Exercise is linked with a lower risk of sarcopenic obesity in humans (3% or 2% vs 19%).

    “Lifelong competitive sport participation leads to lower prevalence of sarcopenic obesity than a recreationally active lifestyle.”

    Humansmales

    Body composition in male lifelong trained strength, sprint and endurance athletes and healthy age-matched controls

    Frontiers in sports and active living

  4. Exercise is linked with a lower risk of sarcopenic obesity in humans (p < 0.01).

    “those exercising ≥ 3 times/week were less likely to have obesity, sarcopenia, and sarcopenia obesity in all groups (p < 0.01), except for sarcopenia in older males and females (p > 0.05).”

    Humans≥ 3 times/week

    Associations of physical activity with sarcopenia and sarcopenic obesity in middle-aged and older adults: the Louisiana osteoporosis study

    BMC public health

  5. Exercise is associated with sarcopenic obesity in humans.

    “regular exercise, physical inactivity, and sedentary time among the behavioral factors”

    Review

    Risk factors associated with sarcopenic obesity in older adults: A meta-analysis and systematic review

    Clinical nutrition ESPEN

  6. Exercise is associated with sarcopenic obesity in humans (17% (95% CI: 8-29%)).

    “Subgroup analysis according to lifestyle factors demonstrated that the SO prevalence was 17% (95% CI: 8-29%, I2 = 99.5%, P < 0.01) in older adults without exercise habits.”

    Review

    Prevalence of sarcopenic obesity in the older non-hospitalized population: a systematic review and meta-analysis

    BMC geriatrics

  7. Exercise lowers the risk of sarcopenic obesity.

    “According to accumulating data, exercise can increase the release of myokines from diverse tissues into the blood and postpone the SO onset and progression”

    Review

    Myokine, a key cytokine for physical exercise to alleviate sarcopenic obesity

    Molecular biology reports

More on Exercise

Type 2 diabetes

upin humans7+9% higher likelihoodHR 2.11

7 studies
  1. Type 2 diabetes is associated with sarcopenic obesity in humans (compared with non-diabetic individuals) (4.9% vs 0.5%).

    “sarcopenic obesity was observed in 4.9% of those with T2D and 0.5% of non-D individuals (P < 0.001)”

    Humanscompared with non-diabetic individualsn = 930

    Clinical characteristics of Sarcopenic obesity in Japanese people with type 2 diabetes: A post hoc analysis of the sub-cohort iDIAMOND study

    Journal of diabetes investigation

  2. Type 2 diabetes is associated with sarcopenic obesity in humans (T2DM vs controls) (42.5% vs. 16.7%, p<0.001).

    “Sarcopenic obesity was identified more frequently in the T2DM group compared with controls (42.5% vs. 16.7%, p<0.001).”

    HumansT2DM vs controlsfemalesn = 240

    INTERRELATIONSHIPS BETWEEN SARCOPENIC OBESITY, VITAMIN D STATUS, AND INSULIN RESISTANCE IN BULGARIAN POSTMENOPAUSAL WOMEN WITH TYPE 2 DIABETES MELLITUS

    Veredas do Direito Direito Ambiental e Desenvolvimento Sustentável

  3. Type 2 diabetes is associated with sarcopenic obesity in humans (type 2 diabetes) (72%).

    “SO was present in 72% of the sample.”

    Humanstype 2 diabetesn = 100

    Variability in muscle function deficits and clinical identification of sarcopenic obesity in older adults with type 2 diabetes

    Frontiers in medicine

  4. Sarcopenic obesity is linked with a higher risk of type 2 diabetes in humans (normoglycaemia) (HR = 2.11; 95% CI: 1.10-4.04).

    “participants with sarcopenic obesity, but not sarcopenia only or obesity only, exhibited a higher risk of progression from normoglycaemia to diabetes (HR = 2.11; 95% CI: 1.10-4.04)”

    Humansnormoglycaemia2011-2015n = 4,637

    The effect of sarcopenic obesity on glycaemic status based on fasting plasma glucose and glycated haemoglobin: A prospective cohort study

    Diabetes, obesity & metabolism

  5. Type 2 diabetes is linked with a higher risk of sarcopenic obesity in humans (2.4-fold greater odds (1.1-5.0)).

    “2.4-fold greater odds (1.1-5.0) of sarcopenic obesity after adjustment.”

    Humansn = 750

    Unraveling the enigma of sarcopenia and sarcopenic obesity in Indian adults with type 2 diabetes - a comparative cross-sectional study

    Clinical diabetes and endocrinology

  6. Type 2 diabetes is linked with a higher risk of sarcopenic obesity in older adults with diabetes (9.0% higher likelihood).

    “PSM analysis revealed a 9.0% higher likelihood of SO in older adults with DM than those without DM.”

    Humansin older adults with diabetes

    Sarcopenic Obesity Burden, Determinants, and Association With Risk of Frailty, Falls, and Functional Impairment in Older Adults With Diabetes: A Propensity Score Matching Analysis

    Cureus

  7. Sarcopenic obesity raises the risk of type 2 diabetes in humans.

    “Sarcopenic obesity has been associated with an increased risk of cardiovascular diseases, type 2 diabetes, frailty, disability, and mortality.”

    Review

    WHY SARCOPENIC OBESITY IS THE STRATEGIC INTERSECTION? – A NARRATIVE REVIEW

    International Journal of Innovative Technologies in Social Science

More on Type 2 diabetes

Multidisciplinary weight-loss program

downin humans1

1 study
  1. Multidisciplinary weight-loss program lowers the risk of sarcopenic obesity in patients with sarcopenic obesity at admission (42.6% (n = 80) out of 188 SO patients at admission resulted in not being sarcopenic).

    “At the end of the multidisciplinary program, 42.6% (n = 80) out of 188 SO patients at admission resulted in not being sarcopenic (No SO discharge), while for 108 patients, the SO condition was unchanged (SO discharge).”

    Human trialin patients with sarcopenic obesity at admission4 weeksn = 188

    Muscle Strength and Phase Angle Are Potential Markers for the Efficacy of Multidisciplinary Weight-Loss Program in Patients with Sarcopenic Obesity

    Journal of clinical medicine

  2. Multidisciplinary weight-loss program lowers the risk of sarcopenic obesity in humans (sarcopenic obesity) (42.55% (80 patients)).

    “At discharge, 80 patients (42.55%) were no longer classified as sarcopenic and showed significant improvements in HGS.”

    Human trialsarcopenic obesity4-weekn = 188

    Muscle Strength and Phase Angle Are Potential Markers for the Efficacy of Multidisciplinary Weight-Loss Program in Patients with Sarcopenic Obesity

    Journal of clinical medicine

More on Multidisciplinary weight-loss program

Laparoscopic sleeve gastrectomy

downin humans1

1 study
  1. Laparoscopic sleeve gastrectomy lowers the risk of sarcopenic obesity in humans (evaluated by ASM/weight index) (from 10/11 to 4/11).

    “ten of eleven patients met SO-risk criteria at baseline and at one month postoperatively, decreasing to four of eleven by six months”

    Human trialevaluated by ASM/weight indexsix monthsfemalesn = 11

    Preliminary assessment of sarcopenic obesity risk after sleeve gastrectomy using dual-modality imaging: a six-month MRI and DXA pilot study in women

    Frontiers in aging

More on Laparoscopic sleeve gastrectomy

Weight-management program

downin humans1OR 0.09

1 study
  1. Weight-management program lowers the risk of sarcopenic obesity in humans (-91% risk (OR = 0.09; 95% CI: 0.02-0.56)).

    “WL% ≥ 5% combined with an active lifestyle (i.e., ≥8000 steps/day), decreased the risk of SO by 91% (OR = 0.09; 95% CI: 0.02-0.56)”

    Human trialsix monthsn = 41

    Can Intentional Weight Loss Ameliorate Sarcopenia in Individuals with Obesity? A Longitudinal Interventional Study

    Clinics and practice

More on Weight-management program

All 380

Trial sponsors

Funding

29 grants since 2016

Japan Society for the Promotion of Science¥67.6MNational Institute on Aging$1.3MUS Department of Veterans Affairs

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Sarcopenic obesity is associated with frailty and disability in human observational studies, cognitive impairment in community-dwelling older adults, and higher mortality in dialysis patients. A trial reports reversal with power training in older women, while trials of semaglutide and a multidisciplinary weight-loss program report reductions in sarcopenic obesity.

  2. Summary rewritten as its findings changed.

    As it read before

    Human studies link sarcopenic obesity to frailty, falls, disability and cognitive impairment, while dialysis cohorts associate it with higher mortality. A human trial reports reduced sarcopenic obesity with semaglutide; a trial in older women reports a reduction with power training.

  3. Summary rewritten as its findings changed.

    As it read before

    Human studies associate sarcopenic obesity with frailty, declining physical performance, cardiometabolic disease, and PhenoAge acceleration. After major abdominal cancer surgery, a human study links it to longer hospital stays and higher mortality but reports no increase in postoperative complications.

  4. Summary rewritten as its findings changed.

    As it read before

    Human studies link sarcopenic obesity to impaired cognition, memory, and attention, higher C-reactive protein, altered lipid profiles, and urinary incontinence in females. Reviews also associate it with mortality, cardiovascular disease, and altered physical function, while exercise reduces risk in menopausal females.

  5. Summary written from the findings.

Latest

Dec 2025: 30Jan 2026: 30Feb 2026: 44Mar 2026: 36Apr 2026: 25May 2026: 32Jun 2026: 38Jul 2026: 28Aug 2026: 30Sep 2026: 35Oct 2026: 42Nov 2026: 16386 papers in 12 months
Osteoarthritis and Cartilage Open

Obesity with poor muscle health linked to worse knee arthritis

Obesity with poor muscle health was linked to 2.54 times the odds of developing knee arthritis with symptoms over six years compared with people with obesity alone.Obesity with poor muscle health was linked to 2.54 times the odds of developing knee arthritis with symptoms over six years compared with people with obesity alone.

Cohort · 1,108 peopleMuscle
Frontiers in Public Health

Muscle and fat estimates help assess health risks in adults

Equations developed in 38,542 UK Biobank participants helped assess 168,875 adults at high risk of obesity accompanied by low muscle mass and strength.Equations developed in 38,542 UK Biobank participants helped assess 168,875 adults at high risk of obesity accompanied by low muscle mass and strength.

Accepted, not yet published: cohort · 168,875 peopleBiomarkers
Adolescencia E Saude

Intervals added more muscle in older adults with sarcopenic obesity

Muscle mass in the arms and legs rose 0.70 kg with high-intensity intervals versus 0.11 kg with moderate continuous exercise over 12 weeks.Muscle mass in the arms and legs rose 0.70 kg with high-intensity intervals versus 0.11 kg with moderate continuous exercise over 12 weeks.

Randomized trial · 35 peopleSarcopenic obesity
iScience

Fat metabolism linked to muscle problems in aging obese mice

Female mice fed a high-fat diet for seven months developed obesity, but signs of metabolic exhaustion tracked differences in muscle dysfunction rather than obesity…Female mice fed a high-fat diet for seven months developed obesity, but signs of metabolic exhaustion tracked differences in muscle dysfunction rather than obesity severity.

Mouse study · 70 miceLipid and ceramide metabolism

See all 1,405 papers on sarcopenic obesity